DNA microarray diagnostic market is set to reach $500m by 2010
This article was originally published in Clinica
Executive Summary
So far, only a smattering of clinical diagnostics firms are selling DNA microarray-based assays. But following advancements in the field, clinical DNA microarrays are now on the brink of a boom and are likely to generate a $500m niche market in just two years time, according to Bertrand Jordan, founder and former head of genetics consortium Genopole, and scientific consultant for three microarray companies. Clinica's Claire Thomas caught up with Dr Jordan shortly after the recent Advances in Microarray Technology Conference in Edinburgh, Scotland
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.